【Bora】Subsidiary Bora Pharmaceuticals Inc. Announces Signing of Long-Term Manufacturing Agreement
Bora's subsidiary, Bora Pharmaceuticals Inc., has signed a 10-year long-term manufacturing agreement with a top 20 global pharmaceutical company. The contract covers a range of services including development, manufacturing, packaging, and analysis, and is expected to positively impact future revenue and strengthen Bora's position as a strategic CDMO partner.
📋 Article Processing Timeline
- 📰 Published: May 18, 2026 at 09:00
- 🔍 Collected: May 19, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 19, 2026 at 08:31 (31 min after Collected)
1. Date of Occurrence: 115/05/18
2. Counterparty to the contract or commitment: Counterparty (undisclosed due to confidentiality agreement)
3. Relationship with the Company: Non-related party
4. Start and end date of the contract or commitment: Effective from the signing date for a term of 10 years, with an automatic renewal for 2 years upon expiration
5. Main content: To provide various support services including but not limited to development, manufacturing, packaging, and analysis during the contract period.
6. Restrictive covenants: As per the contract
7. Commitments: Compliance and cooperation with ESG regulations, with other terms as per the contract
8. Other important agreements: As per the contract
9. Impact on company's finance and business: Positive effect on the company's future revenue and operational scale
10. Specific purpose: To strengthen Bora's positioning as a long-term CDMO strategic partner for international pharmaceutical companies, continuously expand the CDMO business, and actively enter the field of new drug and biologics manufacturing
11. Other relevant information: The counterparty is a top 20 global pharmaceutical company.
2. Counterparty to the contract or commitment: Counterparty (undisclosed due to confidentiality agreement)
3. Relationship with the Company: Non-related party
4. Start and end date of the contract or commitment: Effective from the signing date for a term of 10 years, with an automatic renewal for 2 years upon expiration
5. Main content: To provide various support services including but not limited to development, manufacturing, packaging, and analysis during the contract period.
6. Restrictive covenants: As per the contract
7. Commitments: Compliance and cooperation with ESG regulations, with other terms as per the contract
8. Other important agreements: As per the contract
9. Impact on company's finance and business: Positive effect on the company's future revenue and operational scale
10. Specific purpose: To strengthen Bora's positioning as a long-term CDMO strategic partner for international pharmaceutical companies, continuously expand the CDMO business, and actively enter the field of new drug and biologics manufacturing
11. Other relevant information: The counterparty is a top 20 global pharmaceutical company.